Treatment of pancreatic cancer: Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine

International Journal of Pancreatology

Volumn 22, Issue 2, 1997, Pages 81-93

  Rosenberg, Lawrence ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Gemcitabine; Octreotide; Pancreatic cancer; Somatostatin analogs; Tamoxifen; Treatment

Indexed keywords

AMONAFIDE; ANTIESTROGEN; DIAZIQUONE; EDATREXATE; FAZARABINE; FLUOROURACIL; GEMCITABINE; IPROPLATIN; MITOGUAZONE; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TRIMETREXATE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; FORECASTING; HORMONE ANTAGONISTS; HUMANS; PANCREATIC NEOPLASMS; SOMATOSTATIN; TAMOXIFEN;

EID: 0030728565     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Evans DB, Abbruzzese JL, Rich TR. Cancer of the pancreas, in Cancer: Principles and Practice of Oncology, Devita VT, Hellman S, Rosenberg SA, eds. Lippincott, Philadelphia, 1997, pp. 1054-1087.
2. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA 1995; 45: 8-30.
3. Gudjonsson B. Cancer of the pancreas. Cancer 1987; 60: 2284-2303.
4. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77-81.
5. Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8: 540-545.
6. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6: 19-28.
7. Williamson RCN. Pancreatic cancer: the greatest oncologic challenge. Br Med J 1988; 296: 445,446.
8. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984; 8: 808-821.
9. Douglass H. Adjuvant therapy for pancreatic cancer. World J Surg 1995; 19: 170-174.
10. American Cancer Society Cancer Facts and Figures - 1991. American Cancer Society, 1991.
11. Connolly M, Dawson P, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206: 366-373.
12. Singh S, Longmire W, Reber H. Surgical palliation for pancreatic cancer: the UCLA experience. Ann Surg 1990; 212: 132-139.
13. Ries LAG, Miller BA, Hankey BF, et al., eds. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs, National Cancer Institute, IH pub. No. 94-2789. Bethesda, MD, 1994, 356-368.
14. Blackstock AW, Cox AD, Tepper JE. Treatment of pancreatic cancer: current limitations, future possibilities. Oncology 1996; 10: 301-303.
15. Flanders TY, Foulkes WD. Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet 1996; 33: 889-898.
16. Abruzzese JL. Pancreatic cancer: Overview of current and future therapeutic approaches. Educational Book of the American Society of Clinical Oncology, 33rd Annual Meeting, Denver, CO, May 17-20, 1997; pp. 65-70.
17. Rivenson A, Hoffman D, Prokopczyk B, et al. Induction of lung and exocrine pancreatic tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988; 48: 6912-6917.
18. Pour PM, Rivenson A. Induction of a mixed ductal-squamous-islet cell carcinoma in a rat treated with a tobacco-specific carcinogen. Am J Pathol 1989; 134: 627-631.
19. Hoffman D, Rivenson A, Chung FL, et al. Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis. Crit Rev Toxicol 1991; 21: 305-311.
20. Ogawa T, Makino T, Mizumoto K, et al. Promoting effect of truncal vagotomy on pancreatic carcinogenesis initiated with N-nitrosobis- (2-oxopropyl) amine in Syrian golden hamsters. Carcinogenesis 1991; 12: 1227-1230.
21. Corra S, Kazakoff K, Lawson TA, et al. Cholecystokinin inhibits DNA alkylation induced by N-nitrosobis (2-oxopropyl) amine (BOP) in hamster pancreas. Cancer Lett 1992; 62: 251-256.
22. Hoffman D, Rivenson A, Abbi R, et al. A study of tobacco carcinogenesis: effect of the fat content of the diet on the carcinogenic activity of 4 (methylnitros-amino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res 1993; 53: 2758-2761.
23. Rosenberg L, Brown RA, Duguid WP. Development of experimental cancer in the head of the pancreas by surgical induction of tissue injury. Am J Surg 1984; 147: 146-151.
24. Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994; 86: 1510-1516.
25. La Vecchia C, Boyle P, Francesschi S, et al. Smoking and cancer with emphasis on Europe. Eur J Cancer 1991; 27: 94-104.
26. Yeo C, Cameron J, Lillemoe K, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. Ann Surg 1995; 221: 721-733.
27. Rothenberg ML. New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology 1996; 10: 18-22.
28. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996; 78(3 Suppl): 627-632.
29. Andersen JR, Friss-Mollek A, Hancke S, et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic adenocarcinoma. Scand J Gastroenterol 1981; 16: 973.
30. Frey C, Twomey P, Keehn R, et al. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veteran Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981; 47: 27-32.
31. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multcentre trial. Br Med J 1980; 281: 1589-1591.
32. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic cancer: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-2212.
33. Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreatic cancer. Semin Oncol 1994; 21: 58-66.
34. Bukowski RM. Role of chemotherapy in patients with adenocarcinoma of the pancreas. Adv Oncol 1995; 11: 25.
35. Carter SK. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 3: 193.
36. Hubbard KP, Pazdur R, Ajani JA, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol 1992; 15: 524-527.
37. Carlson RW, Doroshow JH, Odujinrin OO, et al. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas: a phase II study of the Northern California Oncology Group. Invest New Drugs 1990; 8: 387-389.
38. Casper ES, Schwartz GK, Johnson B, et al. Phase II trial of edatrexate in patients with advanced pancreatic cancer. Invest New Drugs 1992; 10: 313-316.
39. Casper ES, Schwartz GK, Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992; 10: 205-209.
40. Bukowski RM, Fleming TR, MacDonald JS, et al. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: a Southwest Oncology Group study. Cancer 1993; 71: 322-325.
41. Linke K, Pazdur R, Abbruzzese J, et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 1991; 9: 353-356.
42. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-4422.
43. Heinemann V, Hertel LW, Grindley GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluoro-2′-deoxycytidine and 1-β-D arabinofuranosyl-cytosine. Cancer 1988; 48: 4024-4031.
44. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
45. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
46. Andersen JS, Burris HA, Casper E, et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Am Soc Clin Oncol 1994; 13: A1600.
47. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
48. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-353.
49. Gelber RD. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol 1996; 7: 335-337.
50. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
51. Abbruzzese JL, Levin B, Ajani JA, et al. A phase I trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal cancer. Cancer Res 1989; 49: 4057-4061.
52. Abbruzzese JL, Levin B, Ajani JA, et al. A pilot phase II trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Modif 1992; 9: 522-527.
53. Andren-Sandberg A, Borg S, Dawiskiba I, Ferno M. Estrogen receptors and estrogen binding protein in pancreatic cancer. Digestion 1982; 25: 12.
54. Berz C, Hollander C, Miller B. Endocrine responsive pancreatic carcinoma steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 1986; 46: 2276-2281.
55. Greenway B, Iqbal MJ, Johnson PJ, Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 1981; 283: 751-753.
56. Satake K, Yoshimoto T, Mukai R, Umeyama K. Estrogen receptors in 7,12-dimethylbenz (a) anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. Clin Oncol 1982; 8: 49-54.
57. Sandberg AA, Rosenthal HE. Steroid receptors in exocrine glands: the pancreas and prostate. J Steroid Biochem 1979; 11: 293-299.
58. Pousette A, Carlstrom K, Skoldefors H, Wilking N, Thieve NO. Purification and partial characterization of a 17β-estradiol-binding macromolecule in the human pancreas. Cancer Res 1982; 42: 633-637.
59. Morita S, Motohara T, Ogawa K, et al. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas - preliminary study. Nippon Igaku Hoshasen Gakkai Zasshi 1992; 52: 1686-1688.
60. Thieve NO, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas - a hormone sensitive tumor? A preliminary report on Novadex treatment. Clin Oncol 1983; 9: 193-197.
61. Tonnesen K, Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol 1986; 12: 69,70.
62. Wong A, Chan A. Survival benefit of tamifen therapy in adenocarcinoma of pancreas. Cancer 1993; 71: 2200-2203.
63. Bakkevold KE, Pettersen A, Arnesjo B, et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of vater. Br J Surg 1990; 77: 725-730.
64. Crowson MC, Dorrell A, Rolfe EB, Fielding WL. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 1986; 12: 335,336.
65. Taylor OM, Benson EA, McMahon MJ, et al. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma: the Yorkshire Gastrointestinal Tumor Group. Br J Surg 1993; 80: 384-386.
66. Rosenberg L, Barkun A, Denis M, et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 23-28.
67. Costanzi J, Chun H, Mittelman A, et al. Phase I/II clinical trial of onconase (ONC) plus tamoxifen (TMX) in patients (pts) with advanced pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 1994; 13: A608.
68. Horimi T, Takasaki M, Toki A, Nishimura W, Morita S. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology 1996; 43: 1225-1229.
69. Couldwell WT, Hinton DR, He S, et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 1994; 345: 43-46.
70. Kang Y, Cortina R, Perry RP. Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 1996; 88: 279-284.
71. Perry RR, Kang Y, Greaves B. Effect of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995; 2: 238-245.
72. Pollack IF, Randall MS, Kristofik MP, et al. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma cell lines in vitro. Cancer Res 1990; 50: 7134-7138.
73. Toms SA, Casey G, Herchergs A, et al. Tamoxifen-induced p53 independent apoptosis in a human glioblastoma cell line. Proc Am Assoc Cancer Res 1995; 36: A47.
74. Vertosick FT, Selker RG, Randall MS, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol 1994; 19: 97-103.
75. Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990; 62: 627-630.
76. Fekete M, Zalatnai A, Comura-Schally AM, Schally AV. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 1989; 4: 521-528.
77. Pinski J, Milovanovic S, YanoT, Hamaoui A, Radulovic S, Cai R-Z, et al. Biological activity and receptor binding characteristics of various human tumors of acetylated somatostatin analogs. Proc Soc Exp Biol Med 1992; 200: 49-56.
78. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JGH, Lamberts SWJ. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988; 95: 760-763.
79. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hssTR1-5) are functionally coupled to adenyl cyclase. Biochem Biophys Res Commun 1994; 198: 605-612.
80. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 1994; 134: 301-306.
81. Johnson LR. Effects of gastrointestinal hormones on pancreatic growth. Cancer 1981; 47: 1640-1645.
82. Comaru-Schally M, Schally AV. LH-RH agonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer, in International Symposium on Gn-RH Analogues in Cancer and Human Reproduction, Lunefield B, Vickery B, eds. Kluwer, Boston, MA, 1990; pp. 203-210.
83. Konturek SJ, Bilski J, Jaworek J, Tasler J, Schally AV. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc Soc Exp Biol Med 1988; 187: 241-249.
84. Stoscheck CM, King LE Jr. Role of epidermal growth factor in carcinogenesis. Cancer Res 1986; 46: 1030-1037.
85. Goustin AS, Leof EB, Shipley GS, Moses HL. Growth factors and cancer. Cancer Res 1986; 46: 1015-1029.
86. Korc M, Magnum BE. Recycling of epidermal growth factor in a human pancreatic carcinoma cell line. Proc Natl Acad Sci USA 1985; 82: 6172-6175.
87. Lamberts SWJ, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281-287.
88. Pollak M, Constantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82: 1693-1697.
89. Pollak M, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Res 1989; 9: 889-891.
90. Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 1994; 203(1): 253-259.
91. Poston GJ, Townsend CM Jr, Rajaraman S, Thompson JC, Singh P. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 1990; 5: 151-157.
92. Morisset J, Genik P, Lord A, Solomon TE. Effects of chronic administration of somatostatin on rat exocrine pancreas. Regul Pept 1982; 4: 49-58.
93. Upp JR Jr, Olson D, Poston GJ, Alexander RW, Townsend CM Jr, Thompson JC. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg 1988; 155: 29-35.
94. Davies NM, Kapur P, Gillespie J, Schally AV, Guillou PJ, Poston GJ. Inhibitory effect of somatostatin analog RC-160 on EGF- and transforming growth factor alpha (TGF-A)-stimulated pancreatic cancer growth in vivo. Br J Cancer 1991; 64(Suppl 15): 4.
95. Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, et al. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies. J Steroid Biochem Mol Biol 1990; 37: 1061-1067.
96. Szende B, Srkalovic G, Schally AV, Lapis K, Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer 1990; 65: 2279-2290.
97. Paz-Bouza JR, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogues of somatostatin and luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1987; 84: 1112-1116.
98. Poston GJ, Gillespie J, Guillou PJ. Biology of pancreatic cancer. Gut 1991; 32: 800-812.
99. Szende B, Zalatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancer of hamsters after administration of analogs of luteinizing hormone releasing hormone and somatostatin. Proc Natl Acad Sci USA 1989; 86: 1643-1647.
100. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989; 86: 2003-2007.
101. Buscail L, Delesque N, Estere J-P, Saint-Laurent N, Prats H, Clerc P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994; 91: 2315-2319.
102. Vennin PH, Peyret JP, Bonneterre J. Effect of the long-acting somatostatin analogue SMS 201-995 in advanced breast cancer. Anticancer Res 1989; 9: 153-156.
103. Guliana JM, Guillausseau PJ, Caron, Siame-Mourot C, Calmettes C, Modigliant E. Effects of short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm Metab Res 1989; 21: 584-586.
104. Kraenzlin ME, Ch'ng JC, Wood SM, Carr DH, Bloom SR. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185-187.
105. Parmar H, Bogden A, Mollard M, de Rouge B, Phillips RH, Lightman SL. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 1989; 16: 95-115.
106. Ebert M, Friess H, Beger H, et al. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994; 55(Suppl 1): 48-51.
107. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Brun C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 1994; 54; 6334-6337.
108. Yousefi S, Vaziri N, Carandang G, Le W, Yamamoto R, Granger G, Ocariz J, Cesario T. The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells. Br J Cancer 1991; 64: 243-246.
109. Niedermuhlbichler M, Wiedermann CJ. Suppression of superoxide release from human monocytes by somatostatin-related peptides. Regul Peptides 1992; 41: 39-47.
110. Weckbecker G, Raulf F, Tolcsvai L, Bruns C. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 1996; 57(Suppl 1): 22-28.
111. Radulovic S, Nagy A, Szoke B, et al. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett 1992; 62: 263-271.